Zoledronic Acid in Combination With Interleukin-2 to Expand Vγ9Vδ2 T Cells After T-replete Haplo-identical Allotransplant
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Patients receiving haplo-SCT are at high-risk of relapse. Vγ9Vδ2 T cells exhibit is a
well-known population able to exert cytotoxicity toward a large range of tumor in vitro or in
vivo. Activating and expanding Vγ9Vδ2 T cells early after haplo-SCT by using a combination of
Zoledronic acid and low-dose interleukine (IL) -2 may be of benefit for patients by reducing
incidence of relapse. The optimal dose of IL-2 to use remains to be determined.
This will be a Phase 1 3+3 escalation study. Three to 15 patients are planned. It will be
proposed to Patients who refuse to participate to have samples collected until day +70 to
study immune and gamma/delta T cells reconstitutions after haplo-transplant.